These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
S&P 500 Gains and Losses Today: Pepsi Stock Turns Higher; Elevance Health Tumbles
Major U.S. equities indexes pushed higher Thursday as a report revealed an increase in retail sales in June, suggesting that consumer spending remains strong despite tariff concerns.
Elevance Health Q2 Earnings Miss Estimates on Rising Medical Costs
ELV's Q2 EPS slides 12.6% y/y and misses estimates as rising Medicaid and ACA costs weigh on the results.
Elevance Health, Inc. (ELV) Q2 2025 Earnings Call Transcript
Elevance Health, Inc. (NYSE:ELV ) Q2 2025 Earnings Conference Call July 17, 2025 8:30 AM ET Company Participants Felicia Farr Norwood - Executive VP & President of Government Health Benefits Gail Koziara Boudreaux - President, CEO & Director Mark Bradley Kaye - Executive VP & CFO Morgan Kendrick - Corporate Participant Nathan Allen Rich - Vice President of Investor Relations Peter David Haytaian - Executive VP and President of Carelon & CarelonRx Conference Call Participants Albert J. William Rice - UBS Investment Bank, Research Division Andrew Mok - Barclays Bank PLC, Research Division Ann Kathleen Hynes - Mizuho Securities USA LLC, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Benjamin Whitman Mayo - Leerink Partners LLC, Research Division David Howard Windley - Jefferies LLC, Research Division Erin Elizabeth Wilson Wright - Morgan Stanley, Research Division George Robert Hill - Deutsche Bank AG, Research Division Jason Paul Cassorla - Guggenheim Securities, LLC, Research Division Joshua Richard Raskin - Nephron Research LLC Justin Lake - Wolfe Research, LLC Kevin Mark Fischbeck - BofA Securities, Research Division Lance Arthur Wilkes - Sanford C.
Elevance Health (ELV) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance Health: Should You Buy ELV Stock Ahead Of Its Upcoming Earnings?
Elevance Health (NYSE:ELV) is set to report its earnings on Thursday, July 17, 2025. For traders focused on events, analyzing past stock performance surrounding earnings announcements can yield valuable insights and potentially improve trading strategies.
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?
ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.
Elevance Health (ELV) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Earnings Preview: Elevance Health (ELV) Q2 Earnings Expected to Decline
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health: A Bargain At 11x Earnings
Elevance Health is undervalued after a 27% drop, trading at the low end of its historical P/E range with significant upside potential. Managed care organizations like Elevance benefit from scale, strong network effects, and high returns on equity, especially in key Blue Cross/Blue Shield markets. Demographic tailwinds from an aging U.S. population and improving Medicaid profitability should drive long-term growth for Elevance.
Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
Strong capital efficiency and commercial growth make ELV appealing, but regulatory and cost headwinds keep investors cautious.
Elevance Health: Carelon Growth Not Fully Appreciated
Elevance Health, Inc.'s Q1 results showed stable Medicare utilization and reaffirmed guidance, in contrast to sector volatility following UnitedHealth Group's rough earnings miss. Medicaid pressures remain, but rate negotiations and targeted acquisitions may support margin recovery by 2026. Carelon Services is growing rapidly, offering diversification away from premium-driven revenue.
